NASDAQ:KZIA Novogen (KZIA) Stock Price, News & Analysis $9.53 +2.71 (+39.74%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$8.80 -0.73 (-7.65%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Novogen Stock (NASDAQ:KZIA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novogen alerts:Sign Up Key Stats Today's Range$7.80▼$10.7950-Day Range$3.22▼$9.7952-Week Range$2.86▼$79.00Volume10.69 million shsAverage Volume430,898 shsMarket Capitalization$9.60 millionP/E RatioN/ADividend YieldN/APrice Target$57.50Consensus RatingBuy Company Overview Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. Read More Novogen Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreKZIA MarketRank™: Novogen scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNovogen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNovogen has only been the subject of 1 research reports in the past 90 days.Read more about Novogen's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.66% of the float of Novogen has been sold short.Short Interest Ratio / Days to CoverNovogen has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novogen has recently increased by 1,261.11%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovogen does not currently pay a dividend.Dividend GrowthNovogen does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.66% of the float of Novogen has been sold short.Short Interest Ratio / Days to CoverNovogen has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Novogen has recently increased by 1,261.11%, indicating that investor sentiment is decreasing significantly. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Novogen this week, compared to 0 articles on an average week.Search Interest4 people have searched for KZIA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows1 people have added Novogen to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novogen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Novogen is held by insiders.Percentage Held by InstitutionsOnly 30.89% of the stock of Novogen is held by institutions.Read more about Novogen's insider trading history. Receive KZIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novogen and its competitors with MarketBeat's FREE daily newsletter. Email Address KZIA Stock News HeadlinesKazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b TrialJuly 9 at 8:00 AM | prnewswire.comKazia Therapeutics Shares Jump After Data Shows Lead Asset Could Treat Breast CancerJune 11, 2025 | marketwatch.comWARNING: A Digital Dollar Is Still In The WorksA digital dollar could theoretically be used as a surveillance tool for banks, federal agencies, and the Federal Reserve. | GoldCo Precious Metals (Ad)Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)June 11, 2025 | prnewswire.comKazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast CancerJune 5, 2025 | prnewswire.comKazia Therapeutics Highlights Recent Progress and Provides Business UpdateMay 15, 2025 | prnewswire.comVivesto AB: Vivesto signs deal with Kazia Therapeutics to acquire full Cantrixil rightsMarch 31, 2025 | finanznachrichten.deKazia Therapeutics sells IP, trademarks rights to Cantrixil for $1MMarch 31, 2025 | markets.businessinsider.comSee More Headlines KZIA Stock Analysis - Frequently Asked Questions How have KZIA shares performed this year? Novogen's stock was trading at $8.85 on January 1st, 2025. Since then, KZIA stock has increased by 7.7% and is now trading at $9.53. When did Novogen's stock split? Shares of Novogen reverse split before market open on Monday, October 28th 2024.The 1-10 reverse split was announced on Tuesday, October 15th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Novogen? Shares of KZIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novogen investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Today7/09/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KZIA Previous SymbolASX:KZA CIK1075880 Webwww.kaziatherapeutics.com Phone(129) 472-4101Fax61-2-9476-0388Employees12Year FoundedN/APrice Target and Rating Average Price Target for Novogen$57.50 High Price Target$100.00 Low Price Target$15.00 Potential Upside/Downside+503.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick RatioN/A Sales & Book Value Annual Sales$1.51 million Price / Sales6.37 Cash FlowN/A Price / Cash FlowN/A Book Value($9.87) per share Price / Book-0.97Miscellaneous Outstanding Shares1,010,000Free Float997,000Market Cap$9.63 million OptionableOptionable Beta2.64 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:KZIA) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novogen Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Novogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.